UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Harm reduction journal, 2023-09, Vol.20 (1), p.1-141, Article 141

2023

Volltextzugriff (PDF)

Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Harm reduction journal, 2023-11, Vol.20 (1), p.1-170, Article 170

2023

Volltextzugriff (PDF)

Medications for opioid use disorder in professional recovery programs in the United States: Policies and recommendation patterns

The mental health clinician, 2023-06, Vol.13 (3), p.163-164

2023

Volltextzugriff (PDF)

Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy

Archives of public health = Archives belges de santé publique, 2024-04, Vol.82 (1), p.58-58, Article 58

2024

Volltextzugriff (PDF)

Prescribing Syringes to People Who Inject Drugs: Advancing Harm Reduction in Primary Care

Journal of general internal medicine : JGIM, 2023-06, Vol.38 (8), p.1980-1983

2023

Volltextzugriff (PDF)

Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas

JAMA : the journal of the American Medical Association, 2018-11, Vol.320 (18), p.1934

2018

Volltextzugriff (PDF)

The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice

Journal of the American Pharmacists Association, 2023-07, Vol.63 (4), p.1039-1043

2023

Volltextzugriff (PDF)

ACE Inhibitors or ARBs to Prevent CKD in Patients with Microalbuminuria

American family physician, 2016-10, Vol.94 (8), p.652-653

2016

Volltextzugriff (PDF)

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA

Addiction (Abingdon, England), 2021-06, Vol.116 (6), p.1505-1511

2021

Volltextzugriff (PDF)

Increasingly powerful opioid antagonists are not necessary

The International journal of drug policy, 2022-01, Vol.99, p.103457-103457, Article 103457

2022

Volltextzugriff (PDF)

Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder

Journal of the American Pharmacists Association, 2023-09, Vol.63 (5), p.1558-1565.e4

2023

Volltextzugriff (PDF)

State-Level Approaches to Expanding Pharmacists’ Authority to Dispense Naloxone May Affect Accessibility

JAMA internal medicine, 2019-10, Vol.179 (10), p.1442

2019

Volltextzugriff (PDF)

Impact of student pharmacist–led naloxone academic detailing at community pharmacies in Texas

Journal of the American Pharmacists Association, 2020-01, Vol.60 (1), p.81-86

2020

Volltextzugriff (PDF)

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Drug and alcohol dependence, 2022-08, Vol.237, p.109518-109518, Article 109518

2022

Volltextzugriff (PDF)

Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists

Journal of the American Pharmacists Association, 2023-01, Vol.63 (1), p.252-260.e6

2023

Volltextzugriff (PDF)

Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice

Substance Abuse, 2022-12, Vol.43 (1), p.972-987

2022

Volltextzugriff (PDF)

Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective

The International journal of drug policy, 2020-12, Vol.86, p.102939-102939, Article 102939

2020

Volltextzugriff (PDF)

Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction

Journal of the American Pharmacists Association, 2019-11, Vol.59 (6), p.779-782

2019

Volltextzugriff (PDF)

Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review

Journal of the American Pharmacists Association, 2022-11, Vol.62 (6), p.1725-1740

2022

Volltextzugriff (PDF)

Implementation of a Collaborative Model for Opioid Overdose Prevention on Campus

Journal of American college health, 2020-04, Vol.68 (3), p.223-226

2020

Volltextzugriff (PDF)

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic

American journal of health-system pharmacy, 2021-03, Vol.78 (7), p.613-618

2021

Volltextzugriff (PDF)

Guidance for Male Mentors to Support the Safety and Success of Female Mentees

American journal of pharmaceutical education, 2019-12, Vol.83 (10), p.7533-7533, Article 7533

2019

Volltextzugriff (PDF)

A qualitative exploration of unintentional versus intentional exposure to fentanyl among people who use drugs in Austin, TX

Journal of the American Pharmacists Association, 2023-01, Vol.63 (1), p.317-323

2023

Volltextzugriff (PDF)

Naloxone Counseling for Harm Reduction and Patient Engagement

Family medicine, 2017-10, Vol.49 (9), p.730-733

2017

Volltextzugriff (PDF)

A call for compassionate opioid overdose response

The International journal of drug policy, 2024-11, Vol.133, p.104587, Article 104587

2024

Volltextzugriff (PDF)

1 – 25 von 165

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(151)
Mit Volltextzugriff
(131)

Publikationsform

Sprache

Englisch
(165)
Japanisch
(20)

Erscheinungsjahr

n.n

Thema

Science & Technology
(116)
Life Sciences & Biomedicine
(84)
Humans
(53)
Animals
(26)
Pharmacology & Pharmacy
(21)
Physical Sciences
(20)
Female
(19)
Mice
(16)
Male
(15)
Science & Technology - Other Topics
(15)
Tumors
(15)
Biological And Medical Sciences
(14)
Multidisciplinary Sciences
(14)
Astronomy & Astrophysics
(13)
Naloxone
(13)
Pharmacists
(13)
Medical Sciences
(12)
Narcotics
(12)
Physics
(12)
Aged
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Medications for opioid use disorder in professional recovery programs in the United States: Policies and recommendation patterns

Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy

Prescribing Syringes to People Who Inject Drugs: Advancing Harm Reduction in Primary Care

Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas

The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice

ACE Inhibitors or ARBs to Prevent CKD in Patients with Microalbuminuria

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA

Increasingly powerful opioid antagonists are not necessary

Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder

State-Level Approaches to Expanding Pharmacists’ Authority to Dispense Naloxone May Affect Accessibility

Impact of student pharmacist–led naloxone academic detailing at community pharmacies in Texas

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists

Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice

Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective

Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction

Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review

Implementation of a Collaborative Model for Opioid Overdose Prevention on Campus

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic

Guidance for Male Mentors to Support the Safety and Success of Female Mentees

A qualitative exploration of unintentional versus intentional exposure to fentanyl among people who use drugs in Austin, TX

Naloxone Counseling for Harm Reduction and Patient Engagement

A call for compassionate opioid overdose response

Suchergebnisse filtern